Subscribe to RSS

DOI: 10.1055/s-0045-1813710
Peculiarities of Neurofibromatosis–Noonan Syndrome: Clinical, Radiological, and Histological Characteristics Illustrated
Authors
Funding None.
Abstract
Neurofibromatosis–Noonan syndrome (NFNS) is an exceptional disease combining two autosomal dominant conditions: neurofibromatosis type 1 (NF1) and Noonan syndrome. Herein, we report the case of a 37-year-old female patient with a history of Hashimoto thyroiditis who exhibited typical symptoms of pheochromocytoma, which was confirmed with hormonal assessment. On physical examination, she exhibited cutaneous features of NF1. She also had short stature and dysmorphic syndrome consistent with NS. Thus, the diagnosis of NFNS was retained. A cerebral magnetic resonance imaging was carried out, revealing a temporal cavernoma. This case is, to our knowledge, the first report of NFNS with cerebral cavernoma, adding new insight into the clinical spectrum of this rare syndrome. Definitely, gaps remain in our understanding of NFNS, and therefore, other studies are warranted.
Keywords
neurofibromatosis–Noonan syndrome - pheochromocytoma - autoimmune thyroiditis - autoimmune diseases - central nervous system cavernous hemangiomaPatient Consent Statement
The authors confirm that the patient provided written informed consent for publication.
Author Contribution
O.T. and R.H. contributed to the writing of the manuscript. E.H. was responsible for the conception of the study. B.B.A. and J.S. contributed to the study design. S.A. provided materials. S.H. was involved in data collection. H.M. performed the literature review. I.K. supervised the project. The data analysis was conducted by I.B. and A.Z.
Compliance with Ethical Principles
Formal ethical approval is not required for single cases and small case series.
Publication History
Article published online:
03 December 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers 2017; 3 (01) 17004
- 2 Choi J, An S, Lim SY. Current concepts of neurofibromatosis type 1: pathophysiology and treatment. Arch Craniofac Surg 2022; 23 (01) 6-16
- 3 Baldo F, Fachin A, Da Re B, Rubinato E, Bobbo M, Barbi E. New insights on Noonan syndrome's clinical phenotype: a single center retrospective study. BMC Pediatr 2022; 22 (01) 734
- 4 Carcavilla A, Suárez-Ortega L, Rodríguez Sánchez A. et al. [Noonan syndrome: genetic and clinical update and treatment options]. An Pediatr (Engl Ed) 2020; 93 (01) 61.e1-61.e14
- 5 Management of Noonan Syndrome - A Clinical Guideline: Noonan Syndrome Guideline Development Group. In: Noonan Syndrome [Internet]. Elsevier; 2019 [Jan 10, 2024]. p. 159–188. Accessed at: https://linkinghub.elsevier.com/retrieve/pii/B9780128153482099874
- 6 Trimeche O, Sakka R, Hajji E. et al. Portraying the full picture of neurofibromatosis-Noonan syndrome: a systematic review of literature. J Med Genet 2025; 62 (02) 109-116
- 7 Reig I, Boixeda P, Fleta B, Morenoc C, Gámez L, Truchuelo M. Neurofibromatosis-Noonan syndrome: case report and clinicopathogenic review of the Neurofibromatosis-Noonan syndrome and RAS-MAPK pathway. Dermatol Online J 2011; 17 (04) 4
- 8 Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen's disease and pheochromocytomas. J Urol 1999; 162 (05) 1582-1586
- 9 Costa MHS, Ortiga-Carvalho TM, Violante AD, Vaisman M. Pheochromocytomas and paragangliomas: clinical and genetic approaches. Front Endocrinol (Lausanne) 2015; 6: 126
- 10 Jrad M, Ksentini M, Abid S. et al. Pheochromocytoma associated with neurofibromatosis type 1 and Noonan syndrome: a case report and literature review. Biomed J Sci Tech Res 2020; 31 (02) 24018-24024
- 11 Housni B, Elharroudi T, Soufi M, Bouziane M, Azzouzi A. Graves' disease allied with multiple pheochromocytoma. Indian J Endocrinol Metab 2013; 17 (02) 323-325
- 12 Marino G, Michielon A, Musumeci MB, Autore C. Takotsubo syndrome: hyperthyroidism, pheochromocytoma, or both? A case report. Eur Heart J Case Rep 2021; 5 (08) ytab270
- 13 Mnif F, Othmen WB, Ghorbel D, Elleuch M, Salah DB, Abid M. Pheochromocytoma/ganglioneuroma and auto-immunity: report of two cases. J Endocrinol Thyroid Res 2019; 4 (03) 1-5
- 14 Zarate YA, Lichty AW, Champion KJ, Clarkson LK, Holden KR, Matheus MG. Unique cerebrovascular anomalies in Noonan syndrome with RAF1 mutation. J Child Neurol 2014; 29 (08) NP13-NP17
- 15 Tanaka Y, Masuno M, Iwamoto H. et al. Noonan syndrome and cavernous hemangioma of the brain. Am J Med Genet 1999; 82 (03) 212-214
- 16 Kobayashi T, Aoki Y, Niihori T. et al. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat 2010; 31 (03) 284-294
- 17 Wimmer R, Cseh B, Maier B, Scherrer K, Baccarini M. Angiogenic sprouting requires the fine tuning of endothelial cell cohesion by the Raf-1/Rok-α complex. Dev Cell 2012; 22 (01) 158-171
- 18 Rerat K, Parker F, Nasser G. et al. Occurrence of multiple cerebral cavernous malformations in a patient with neurofibromatosis type 1. J Neurol Sci 2015; 350 (1–2): 98-100
